American Well Corporation
NYSE:AMWLMedical - Healthcare Information Services
+$0.24 today
- Market cap
- $171.77M
- Beta
- 1.70
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$5.30
Volume 0.06M
Average 0.07M
AMWL Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
American Well CorporationNYSE: AMWL
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $7.59M fell 2.7% year over year, behind the +5.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 19.5% from the prior quarter. Over 3 fiscal years it compounded at +9.1% a year.
Context
- Depreciation & amortization amounted to 13.6% of revenue in FY2025, up 0.5 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -2.7% toward the trailing-twelve-month pace of +5.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 33.96M USD
- Year-over-year change
- +1.6%
- 4-year CAGR
- +20.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.96M | +1.6% |
| FY2024 | 2024-12-31 | 33.43M | +4.7% |
| FY2023 | 2023-12-31 | 31.92M | +22.0% |
| FY2022 | 2022-12-31 | 26.17M | +62.6% |
| FY2021 | 2021-12-31 | 16.09M | — |
Depreciation & Amortization vs competitors
How AMWL compares with its peers on the latest reported figures
- AMWL's LTM Mar 2026 depreciation & amortization of $34.69M is the largest of the 9 companies compared; the peer median is $1.04M.
- Its year-over-year change of +5.2% is the 4th highest of 9, against a peer median of +4.0%.
- Depreciation & amortization amounts to 14.6% of revenue for AMWL, versus a peer median of 25.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.69M | +5.2% | +9.1% | 14.6% | |
| LTM Mar 2026 | $2.69M | -30.3% | -32.6% | 6.0% | |
| LTM Mar 2026 | $1.74M | +3.4% | — | 44.2% | |
| LTM Mar 2026 | $1.56M | +35.6% | -2.9% | 823.2% | |
| LTM Mar 2026 | $1.12M | +22.5% | +35.7% | — | |
| LTM Mar 2026 | $960K | -46.5% | +26.8% | — | |
| LTM Jun 2026 | $707.29K | +160.0% | +33.2% | 5.8% | |
| LTM Mar 2026 | $645K | -25.8% | +27.3% | — | |
| LTM Mar 2026 | $158K | +4.6% | +29.7% | — | |
| Peer median (excluding AMWL) | $1.04M | +4.0% | +27.3% | 25.1% | |
Competitors are the stored peer set for AMWL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (176.78M) | (272.07M) | (675.16M) | (208.14M) | (95.7M) |
| Depreciation & Amortization | 16.09M | 26.17M | 31.92M | 33.43M | 33.96M |
| Deferred Income Tax | (6.25M) | (2.52M) | (242K) | (243K) | (1.11M) |
| Stock-Based Compensation | 43.81M | 67.68M | 72.25M | 47.54M | 22.01M |
| Change in Working Capital | (27.72M) | (28.1M) | (15.51M) | (9.98M) | (26.8M) |
| Accounts Receivables | (512K) | (8.14M) | 3.25M | (25.01M) | 12.22M |
| Inventory | 1.6M | (1.21M) | 2.09M | 1.9M | 1.17M |
| Accounts Payables | 5.55M | (4.78M) | (2.36M) | 159K | (3.42M) |
| Other Working Capital | (34.35M) | (13.97M) | (18.48M) | 12.97M | (36.77M) |
| Other Non-Cash Items | 9.31M | 16.53M | 438.4M | 57.6M | 1.68M |
| Operating Cash Flow | (141.54M) | (192.32M) | (148.34M) | (127.34M) | (65.95M) |
| Capital Expenditures | (559K) | (10.45M) | (15.25M) | (15.22M) | (21K) |
| Acquisitions (Net) | (159.07M) | (1.96M) | 0 | (3.43M) | 18.32M |
| Purchases of Investments | 2.55M | (499.22M) | (389.99M) | 0 | (1M) |
| Sales of Investments | 100M | 500M | 389.99M | 0 | 0 |
| Other Investing Activities | (2.55M) | 0 | (18.88M) | (15.1M) | (196K) |
| Investing Cash Flow | (59.63M) | (11.63M) | (19.17M) | (18.65M) | 17.1M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 844K |
| Common Stock Repurchased | (15.04M) | (360K) | (586K) | (3K) | (4K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 20.79M | (3.25M) | 2.73M | 1.38M | 0 |
| Financing Cash Flow | 5.75M | (3.61M) | 2.15M | 1.38M | 840K |
| Effect of Forex Changes | (84K) | (305K) | (1.14M) | 887K | 2.02M |
| Net Change in Cash | (195.5M) | (207.87M) | (166.51M) | (143.72M) | (45.99M) |
| Free Cash Flow | (142.1M) | (202.77M) | (163.59M) | (142.56M) | (65.97M) |
American Well Corporation
NYSE:AMWL
Intrinsic Alpha fair value
Locked
Current Price
$11.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.